ArticleEuropean journal of medical research2025
Identification of key genes and regulatory networks associated with atherosclerotic carotid artery stenosis through comprehensive bioinformatics analysis and machine learning.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo identify the potential diagnostic biomarkers and therapeutic targets of atherosclerotic carotid artery stenosis (ACAS), a comprehensive bioinformatics analysis was conducted to identify its related key genes and regulatory networks.
methodsFour datasets, including GSE43292, GSE100927, GSE28829, and GSE198600, were integrated to form the training set, with the GSE163154 dataset serving as the validation set. Subsequently, differential expression and functional enrichment analysis were performed on the training set. In addition, key pathogenic genes were identified using the protein-protein interaction networks, molecular complex detection technique, and three machine learning (ML) algorithms. These identified genes were validated through inter-group differences and receiver operating characteristic (ROC) curve analyses. Immune-related functions and immune cell correlations were analyzed and verified using ACAS plaque tissue samples.
resultsFollowing the analysis, a total of 33 downregulated and 52 upregulated genes were identified. Furthermore, enrichment analysis of gene sets demonstrated that the highly expressed group was involved in cellular receptor signaling, leishmaniasis infection, lysosome, PPAR-signaling, and Toll-like receptor pathways. In contrast, the low-expressed group was involved in mechanisms involving dilated cardiomyopathy, pyruvate metabolism, hypertrophic cardiomyopathy, spliceosome, and TGF-β signaling pathways. Notably, ANPEP, CSF1R, MMP9, and CASQ2 were found to differ significantly between groups. Correlation analysis revealed positive associations between MMP9 expression and neutrophil infiltration, CASQ2 expression and M2 macrophage abundance, and CSF1R expression and M1 macrophage levels.
conclusionConsequently, these genes (ANPEP, CSF1R, MMP9, and CASQ2) may serve as potential biomarkers and therapeutic targets in the diagnosis and treatment of ACAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.